India Xerostomia Therapeutics Market, By Product Type (Saliva Substitutes, Drugs, Salivary Pen, and Others), Type (True Xerostomia and Pseudo Xerostomia Or Symptomatic Xerostomia), Mode of Purchase (Prescription (Rx) and Over The Counter (OTC)), Population (Geriatric and Adults), End User (Dental Clinics, Hospitals, Specialty Clinics, and Home Care), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Sales) - Industry Trends and Forecast to 2030.
India Xerostomia Therapeutics Market Analysis and Insights
India, with its large population, presents a significant market for healthcare products and services, including those related to xerostomia.
The increasing number of chemotherapy and radiotherapy and the growing prevalence of xerostomia are the drivers expected to drive market growth. Major companies are expanding their product portfolios in the country to strengthen their presence for these products and solutions in the market, which is expected to drive market growth.
The high cost associated with xerostomia treatment is expected to restrain market growth. In addition, the side effects associated with the xerostomia treatment are expected to restrain market growth.
- According to a study published in the Journal of Oral Rehabilitation in 2019, the overall prevalence of xerostomia in the general population was estimated to be around 10% to 20%
Data Bridge Market Research analyzes that the India xerostomia therapeutics market is expected to reach the value of USD 25.20 million by 2030, at a CAGR of 5.1% during the forecast period.
2023 to 2030
2021 (Customizable to 2015 – 2020)
Revenue in USD Million
Product Type (Saliva Substitutes, Drugs, Salivary Pen, and Others), Type (True Xerostomia and Pseudo Xerostomia Or Symptomatic Xerostomia), Mode of Purchase (Prescription (Rx) and Over The Counter (OTC)), Population (Geriatric and Adults), End User (Dental Clinics, Hospitals, Specialty Clinics, and Home Care), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Sales)
Market Players Covered
Colgate-Palmolive Company., Sun Pharmaceutical Industries Ltd., Haleon Group of Companies., 3M., Alish Life Saving Impex Private Limited., GC Corporation, ICPA Health Products Ltd, and Saliwell Ltd. among others
Xerostomia, also known as dry mouth, refers to a medical condition characterized by a lack of saliva production in the mouth. Saliva plays a crucial role in maintaining oral health by moistening and lubricating the oral cavity, aiding in digestion, neutralizing acids, and preventing tooth decay. When there is an insufficient amount of saliva, it can lead to various symptoms such as dryness, discomfort, difficulty in speaking, chewing, and swallowing, altered taste, bad breath, and an increased risk of oral infections.
The xerostomia therapeutics market refers to the commercial landscape related to the diagnosis, treatment, and management of dry mouth. It encompasses pharmaceutical companies, medical device manufacturers, and healthcare providers involved in the development and distribution of products and services aimed at addressing xerostomia. This market includes medications, saliva substitutes, oral moisturizers, chewing gums, mouthwashes, and other therapies or interventions designed to alleviate the symptoms and improve the quality of life for individuals with xerostomia.
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
- Rising Use of Chemotherapy and Radiotherapy in the Cancer Treatment
Radiation therapy to the head, face, or neck can cause dry mouth. It can take 6 months or longer after radiation therapy ends for the salivary glands to start producing saliva again. Dry mouth often improves during the first year after radiation treatment. But many people continue to have some level of long-term dry mouth. This is especially if the radiation therapy was directed at the salivary glands. Thus, the increasing adoption of chemotherapy and radiotherapy in cancer treatment is expected to drive market growth.
- Growing Prevalence of Xerostomia
The prevalence of xerostomia is increasing due to the growing aging population. Age by itself is not a cause of xerostomia, but older patients tend to be on multiple medications and have a higher incidence of comorbid conditions. Thus, the growing prevalence of several diseases such as Sjogren’s syndrome, HIV, diabetes, and Alzheimer’s disease which ultimately leads to a rise in the number of patients suffering from xerostomia is expected to drive market growth.
- Advancements in the Pharmaceutical Research and Development
The pharmaceutical sciences represent an evolving and highly dynamic field, and two overreaching trends show an increased effort to develop biologic-based drugs and create more specific or targeted drug delivery techniques. Advancements in pharmaceutical R&D have played a crucial role in improving healthcare outcomes, discovering new treatments, and enhancing patient care, which is expected to drive market growth.
- High Cost Associated with Xerostomia Treatment
The products or devices which are used in the detection of xerostomia are becoming advanced but along with that the procedure for oral diseases diagnostics are also costly which hamper the market growth because the devices which are used in the process of cancer diagnosis getting more expensive which results to increase in the high cost of detection process of xerostomia. Thus, the high cost of xerostomia treatment is expected to restrain market growth.
- Side Effects Associated with Xerostomia Therapies
Xerostomia is one of the most common drug-related adverse effects in the oral cavity. Till date, more than 500 medications have been implicated in the etiology of xerostomia. The use of medications and advancing age are significant risk factors that cause xerostomia in elderly individuals. Thus, the side effects associated with xerostomia treatment are expected to restrain market growth.
Rising Product Collaborations and Partnerships
The market is promoted by the main market players involved in the development work with continuous research for the development of new drugs for xerostomia treatment with additional investments in the core market area. Players are working on product development that has advanced features to detect xerostomia in less time. If any diseases are detected at an early stage, it helps the patient to recover faster and prevent them from spreading to other parts of the body, which motivates market players in the development of new drugs. Increased product and drug collaborations and partnerships are expected to create opportunities for market growth.
Rising Research and Development Activities for the Development of Novel Therapies
The rise in the prevalence of chronic disease has generated interest and a burden on the research and healthcare department. Different manufacturing industries have taken a keen interest to develop new therapies for the treatment of chronic disease. There has been increased research activity regarding active pharmaceutical ingredients. Huge investment is done by the companies to develop novel products which will be used in the treatment of chronic diseases. So many products are under the developmental procedure for the treatment of different kinds of debilitating diseases, which is expected to create opportunities for market growth.
- Lack of Awareness of Xerostomia
The people in emerging countries suffer from several oral diseases more specifically periodontal disease followed by poverty, ignorance concerning health education, poor living conditions, lack of government funding, policy for providing good, and sufficient oral health care. The WHO and FDI are trying to identify these problems and come up with strategies for the improvement of such conditions.
- Lack of Treatments Available for Xerostomia
In today's complicated world, a disease diagnosis is a dynamic element that gives patients crucial knowledge for identifying, avoiding, treating, and controlling their diseases. The requirement for various therapies and treatments is rising with the increasing number of chronic diseases, which is expected to challenge market growth.
- In April 2023, 3M Health Information Systems announced a collaboration with Amazon Web Services (AWS) to accelerate the innovation and advancement of 3M M Modal ambient intelligence. As part of the collaboration, 3M will use AWS Machine Learning (ML) and generative AI services, including Amazon Bedrock, Amazon Comprehend Medical, and Amazon Transcribe Medical, to help expedite, refine, and scale the delivery of 3M's ambient clinical documentation and virtual assistant solutions. This has helped the company to expand its business.
- In October 2022, Haleon Group of Companies invited consumer health startups in India, for the first time, to partner with Re/Wire Health Studio, a game-changing global collaboration and partnership platform from Haleon NEXT, the disruptive innovation arm of the global consumer health company Haleon. This has helped the company to expand its global presence.
India Xerostomia Therapeutics Market Scope
The India xerostomia therapeutics market is segmented into six notable segments based on product type, type, mode of purchase, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- Saliva Substitutes
- Salivary Pen
On the basis of product type, the market is segmented into saliva substitutes, drugs, salivary pen, and others.
- True Xerostomia
- Pseudo Xerostomia or Symptomatic Xerostomia
On the basis of type, the market is segmented into true xerostomia and pseudo xerostomia or symptomatic xerostomia.
Mode of Purchase
- Prescription (Rx)
- Over the Counter (OTC)
On the basis of mode of purchase, the market is segmented into prescription (Rx) and Over the Counter (OTC).
On the basis of population type, the market is segmented into geriatric and adults.
- Dental Clinics
- Specialty Clinics
- Home Care
On the basis of end user, the market is segmented into dental clinics, hospitals, specialty clinics, and home care.
- Retail Pharmacies
- Hospital Pharmacies
- Online Sales
On the basis of distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and online sales.
Competitive Landscape and India Xerostomia Therapeutics Market Share Analysis
The India xerostomia therapeutics market is segmented into six notable segments based on product type, type, mode of purchase, population type, end user, and distribution channel.
The India xerostomia therapeutics market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the India xerostomia therapeutics market are Colgate-Palmolive Company., Sun Pharmaceutical Industries Ltd., Haleon Group of Companies., 3M., Alish Life Saving Impex Private Limited., GC Corporation, ICPA Health Products Ltd, and Saliwell Ltd. among others.